Oculus Innovative Sciences Inc. (NASDAQ:OCLS) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price target of $8.00 for the company, according to Zacks. Zacks has also given Oculus Innovative Sciences an industry rank of 190 out of 265 based on the ratings given to its competitors.
Separately, Maxim Group set a $8.00 price target on shares of Oculus Innovative Sciences and gave the company a “buy” rating in a research report on Friday, November 11th.
Oculus Innovative Sciences (NASDAQ:OCLS) opened at 4.70 on Wednesday. The firm’s 50-day moving average price is $4.39 and its 200-day moving average price is $4.38. Oculus Innovative Sciences has a 12 month low of $3.57 and a 12 month high of $7.15. The firm’s market cap is $19.80 million.
About Oculus Innovative Sciences
Oculus Innovative Sciences, Inc is a specialty pharmaceutical company, which focuses on identifying, developing and commercializing therapies to manage the lives of patients with dermatologic diseases or conditions. The Company’s products treat certain topical skin diseases, including acne, atopic dermatitis, scarring, infections, itch, pain and inflammatory responses.